Image

Melanoma Research

Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA”
10/07/2021

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy”
09/27/2021

Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy

By Kim Margolin, M.D., FACP, FASCO Vaccine background and brief history The word “vaccine” comes from the Latin word vacca…
Blog - Melanoma360
In Plain English
Melanoma Research
Featured image for “Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma”
09/20/2021

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
09/20/2021

USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma”
09/18/2021

Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma

LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer”
08/25/2021

Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer

August 24, 2021  Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma”
08/25/2021

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin”
07/22/2021

FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin

July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Gut Microbes Signal Response to Immune Therapy in Melanoma”
07/12/2021

Gut Microbes Signal Response to Immune Therapy in Melanoma

(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
Blog - Melanoma360
Breaking News
Melanoma Research
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
10/07/2021

Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
Featured image for “Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/27/2021

Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy

By Kim Margolin, M.D., FACP, FASCO Vaccine background and brief history The word “vaccine” comes from the Latin word vacca…
Featured image for “Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy”
Blog - Melanoma360
 | 
In Plain English
 | 
Melanoma Research
09/20/2021

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
Featured image for “Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/20/2021

USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma

09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
Featured image for “USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
09/18/2021

Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma

LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
Featured image for “Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
08/25/2021

Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer

August 24, 2021  Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
Featured image for “Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
08/25/2021

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Featured image for “Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
07/22/2021

FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin

July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
Featured image for “FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
07/12/2021

Gut Microbes Signal Response to Immune Therapy in Melanoma

(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
Featured image for “Gut Microbes Signal Response to Immune Therapy in Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research